GlassScriptPhysician profile
James D Ozeran
NPI 1427060391
$858.35
in general payments reported to CMS, 2019-2025
19 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.64 · 2020: $22.83 · 2021: $17.12 · 2022: $201 · 2023: $224 · 2024: $166 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $528.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $169.98 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $135.76 | 2019-2024 | |
| Servier Pharmaceuticals LLC | $106.46 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $90.87 | 2022-2024 | Ultomiris |
| Pharming Healthcare, INC. | $50.44 | 2023 | Ruconest |
| Rare Disease Therapeutics, INC. | $42.24 | 2024-2025 | Xromi, Purixan |
| Y-Mabs Therapeutics, INC. | $40.52 | 2022-2023 | Danyelza |
| Chiesi USA, INC. | $38.33 | 2022-2025 | Ferriprox |
| Jazz Pharmaceuticals INC. | $33.02 | 2023 | |
| Biomarin Pharmaceutical INC. | $23.71 | 2024 | Roctavian |
| Genetix Biotherapeutics INC | $18.75 | 2023 | |
| Novo Nordisk INC | $16.83 | 2024 | Sogroya |
| Genzyme Corporation | $16.78 | 2023 | |
| Shorla Oncology INC. | $16.26 | 2025 | |
| Grifols USA, LLC | $15.68 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emmaus Medical, INC. | $15.14 | 2019 | |
| Acrotech Biopharma INC. | $14.97 | 2023 | Beleodaq |
| Sanofi-Aventis U.S. LLC | $12.61 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ozeran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.